Detailed product reference
Summaries refer to the listed Japanese product. Eligibility, adjustments and full risks depend on its label and strength; a clinician determines individual treatment.
Product overview
Enhertu is a HER2-directed antibody–drug conjugate, distinct from trastuzumab alone and T-DM1.
Read source section ↗Mechanism of action
Delivers a topoisomerase-I inhibitor into HER2-expressing cells. HER2 expression and mutation are different tests.
Read source section ↗Japanese indications & eligibility
Japanese indications cover selected HER2-defined breast, lung, gastric and other solid cancers under treatment-history conditions.
Read source section ↗Administration & dose differences
Label doses are generally 5.4 mg/kg every three weeks, or 6.4 mg/kg for gastric cancer; some breast regimens combine pertuzumab.
Read source section ↗Adverse effects & key risks
Major concerns include potentially fatal interstitial lung disease, myelosuppression, nausea and cardiac dysfunction.
Read source section ↗Contraindications & special populations
Ingredient hypersensitivity is contraindicated. Assess lung/cardiac disease, liver function and reproductive risks.
Read source section ↗Drug interactions
Check combination drugs and follow product-specific preparation, dilution and infusion requirements.
Read source section ↗Assessment & monitoring
Monitor lung symptoms/imaging, blood counts, liver function and left ventricular function.
Read source section ↗Storage & handling
Unopened vials require 2–8°C refrigeration; preparation and storage after reconstitution follow the label.
Read source section ↗Sources & verification
Product checked ·
- PMDA electronic package insert ↗www.pmda.go.jp
Primary source for mechanism, indications, doses and risks; revision: 2026-09.
- Manufacturer information ↗www.daiichisankyo.co.jp
Official product or related information; professional portals may require identity confirmation.
- Wikipedia: ingredient background ↗en.wikipedia.org
Background reference; Japanese approvals and administration are governed by PMDA sources.
